---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-009170"
form_type: "8-K"
ticker: "BPTH"
cik: "0001133818"
company_name: "BIO-PATH HOLDINGS, INC."
filed_at: "2024-06-14T23:59:59+00:00"
generated_at: "2026-06-01T04:14:57.361739+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bio-Path interim Phase 2 data: 75% CR/CRh/CRi in newly diagnosed AML with prexigebersen combo

## Summary
- Cohort 1 (newly diagnosed): 15/20 evaluable patients achieved CR/CRh/CRi; median age 75, adverse-risk or secondary AML.
- Cohort 2 (relapsed/refractory): 55% of evaluable patients (12/23) achieved CR/CRh/CRi with same triple combination.
- Most common severe adverse events: febrile neutropenia (26%) and sepsis (5%); safety consistent with backbone therapy.
- Company to continue enrollment up to 98 evaluable for Cohort 1 and 54 for Cohort 2.
- Results presented at EHA Congress 2024; CEO highlights potential as additional AML treatment option.

## SEC filing metadata
- accession: 0001558370-24-009170
- form_type: 8-K
- ticker: BPTH
- cik: 0001133818
- company_name: BIO-PATH HOLDINGS, INC.
- filed_at: 2024-06-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133818/000155837024009170/0001558370-24-009170-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133818/000155837024009170/bpth-20240614x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-009170
- JSON: https://secwatch.observer/filing/0001558370-24-009170.json
- Plain text: https://secwatch.observer/filing/0001558370-24-009170.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.